ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast CancerBusiness Wire • 07/25/22
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer StudyBenzinga • 07/19/22
ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based RegimensBusiness Wire • 07/19/22
AstraZeneca acquires blood cancer specialist TeneoTwo for up to US$1.2bnProactive Investors • 07/05/22
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract CancersBusiness Wire • 07/01/22
Nuformix hoping to develop a 'bio-better' version of AstraZeneca blockbusterProactive Investors • 06/29/22
AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast CancerZacks Investment Research • 06/28/22
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenBusiness Wire • 06/27/22
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative DiseaseBusiness Wire • 06/22/22